PLx Pharma Inc. logo

PLXP

PLx Pharma Inc.

$0.92

Earnings Summary

Revenue
$2.08Mn
Net Profits
$-10.79Mn
Net Profit Margins
-517.76%

Highlights

Revenue:

PLx Pharma Inc.’s revenue jumped +Inf% since last year same period to $2.08Mn in the Q1 2022. On a quarterly growth basis, PLx Pharma Inc. has generated 30.85% jump in its revenue since last 3-months.

Net Profits:

PLx Pharma Inc.’s net profit jumped 6.55% since last year same period to $-10.79Mn in the Q1 2022. On a quarterly growth basis, PLx Pharma Inc. has generated -402.75% fall in its net profits since last 3-months.

Net Profit Margins:

PLx Pharma Inc.’s net profit margin jumped NaN% since last year same period to -517.76% in the Q1 2022. On a quarterly growth basis, PLx Pharma Inc. has generated -331.37% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the PLx Pharma Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.56
EPS Estimate Current Year
-0.56

Highlights

EPS Estimate Current Quarter:

PLx Pharma Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.56 - a 22.22% jump from last quarter’s estimates.

EPS Estimate Current Year:

PLx Pharma Inc.’s earning per share (EPS) estimates for the current year stand at -0.56.

Key Ratios

Key ratios of the PLx Pharma Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
-0.39
Return on Assets (ROA)
-0.61
Return on Equity (ROE)
-0.92
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

PLx Pharma Inc.’s earning per share (EPS) jumped 46.58% since last year same period to -0.39 in the Q1 2022. This indicates that the PLx Pharma Inc. has generated 46.58% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. PLx Pharma Inc.’s return on assets (ROA) stands at -0.61.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. PLx Pharma Inc.’s return on equity (ROE) stands at -0.92.

Dividend Per Share (DPS):

PLx Pharma Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-13
-0.72
-0.39
45.83%

Company Information

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

Organisation
PLx Pharma Inc.
Headquarters
Sparta, New Jersey, US
Employees
10
Industry
Health Technology